menu search

Biotech at Good Entry Point for Investors, Analyst Says

Biotech at Good Entry Point for Investors, Analyst Says
Source: Andrew Partheniou (12/20/22) The company, focused on psychedelic-assisted psychotherapies to better treat addiction, is worth more than the CA$10 million the market is valuing it at, noted a Stifel report. Awakn Life Sciences Corp. (AWKN:NEO; AWKNF:OTCQB) is currently undervalued and, thus, providing investors an attractive time to get into the stock, reported Stifel analyst Andrew […]... Read More
Posted: Dec 21 2022, 16:14
Author Name: investmacro
Views: 101981

Search within

Pages Search Results: